Michael D. Fetters

Generating author description...

All published works

Action	Title	Year	Authors
+	Special Issue on COVID-19 and Novel Mixed Methods Methodological Approaches During Catastrophic Social Changes	2021	Michael D. Fetters José F. Molina‐Azorín
+ PDF Chat	Conceptual models to guide integration during analysis in convergent mixed methods studies	2017	Ellen Moseholm Michael D. Fetters
+ PDF Chat	A conceptual model for the development process of confirmatory adaptive clinical trials within an emergency research network	2017	Samkeliso Mawocha Michael D. Fetters Laurie J. Legocki Timothy C. Guetterman Shirley Frederiksen William G. Barsan Roger Lewis Donald A. Berry William J. Meurer
+ PDF Chat	The life cycles of six multi-center adaptive clinical trials focused on neurological emergencies developed for the Advancing Regulatory Science initiative of the National Institutes of Health and US Food and Drug Administration: Case studies from the Adaptive Designs Accelerating Promising Treatments Into Trials Project	2017	Timothy C. Guetterman Michael D. Fetters Samkeliso Mawocha Laurie J. Legocki William G. Barsan Roger Lewis Donald A. Berry William J. Meurer
+ PDF Chat	Attitudes and opinions regarding confirmatory adaptive clinical trials: a mixed methods analysis from the Adaptive Designs Accelerating Promising Trials into Treatments (ADAPT-IT) project	2016	William J. Meurer Laurie J. Legocki Samkeliso Mawocha Shirley M. Frederiksen Timothy C. Guetterman William G. Barsan Roger Lewis Donald A. Berry Michael D. Fetters
+ PDF Chat	Reflections on the adaptive designs accelerating promising trials into treatments (ADAPT-IT) process—Findings from a qualitative study	2015	Timothy C. Guetterman Michael D. Fetters Laurie J. Legocki Samkeliso Mawocha William G. Barsan Roger Lewis Donald A. Berry William J. Meurer
+ PDF Chat	Clinical trialist perspectives on the ethics of adaptive clinical trials: a mixed-methods analysis	2015	Laurie J. Legocki William J. Meurer Shirley Frederiksen Roger Lewis Valerie Durkalski Donald A. Berry William G. Barsan Michael D. Fetters
+ PDF Chat	An Overview of the Adaptive Designs Accelerating Promising Trials Into Treatments (ADAPT-IT) Project	2012	William J. Meurer Roger J. Lewis Danilo A. Tagle Michael D. Fetters Laurie Legocki Scott Berry Jason Connor Valerie Durkalski Jordan Elm Wenle Zhao

Common Coauthors

Coauthor	Papers Together
William J. Meurer	6
William G. Barsan	6
Donald A. Berry	5
Laurie J. Legocki	5
Roger Lewis	5
Samkeliso Mawocha	4
Timothy C. Guetterman	4
Shirley Frederiksen	2
Shirley M. Frederiksen	1
Wenle Zhao	1
Shirley Frederiksen	1
Robert Silbergleit	1
Donald A. Berry	1
Roger J. Lewis	1
Laurie Legocki	1
Yuko Y. Palesch	1
Valerie Durkalski	1
Danilo A. Tagle	1
Scott Berry	1
José F. Molina‐Azorín	1
Jordan Elm	1
Ellen Moseholm	1
Valerie Durkalski	1
Jason Connor	1

Commonly Cited References

Action	Title	Year	Authors	# of times referenced
+ PDF Chat	An Overview of the Adaptive Designs Accelerating Promising Trials Into Treatments (ADAPT-IT) Project	2012	William J. Meurer Roger J. Lewis Danilo A. Tagle Michael D. Fetters Laurie Legocki Scott Berry Jason Connor Valerie Durkalski Jordan Elm Wenle Zhao	5
+ PDF Chat	Clinical trialist perspectives on the ethics of adaptive clinical trials: a mixed-methods analysis	2015	Laurie J. Legocki William J. Meurer Shirley Frederiksen Roger Lewis Valerie Durkalski Donald A. Berry William G. Barsan Michael D. Fetters	4
+ PDF Chat	Bayesian adaptive trials offer advantages in comparative effectiveness trials: an example in status epilepticus	2013	Jason T. Connor Jordan Elm Kristine Broglio	3
+ PDF Chat	Adaptive trial designs: a review of barriers and opportunities	2012	John A. Kairalla Christopher S. Coffey Mitchell A Thomann Keith E. Muller	3
+ PDF Chat	Reflections on the adaptive designs accelerating promising trials into treatments (ADAPT-IT) process—Findings from a qualitative study	2015	Timothy C. Guetterman Michael D. Fetters Laurie J. Legocki Samkeliso Mawocha William G. Barsan Roger Lewis Donald A. Berry William J. Meurer	3
+	Adaptive Design: Results of 2012 Survey on Perception and Use	2014	Caroline C. Morgan Susan Huyck Martin Jenkins Li Chen Alun Bedding Christopher S. Coffey Brenda Gaydos J. Kyle Wathen	3
+ PDF Chat	The Stroke Hyperglycemia Insulin Network Effort (SHINE) trial: an adaptive trial design case study	2015	Jason T. Connor Kristine Broglio Valerie Durkalski William J. Meurer Karen C. Johnston	3
+	Adaptive Designs: Terminology and Classification	2006	Vladimir Dragalin	3
+	Adaptive Designs in Clinical Drug Development—An Executive Summary of the PhRMA Working Group	2006	Paul Gallo Christy Chuang‐Stein Vladimir Dragalin Brenda Gaydos Michael Krams José Cirı́aco Pinheiro	3
+	Barriers and opportunities for implementation of adaptive designs in pharmaceutical product development	2010	Judith Quinlan Brenda Gaydos Jeff Maca Michael Krams	3
+	Impact of Dose Selection Strategies Used in Phase II on the Probability of Success in Phase III	2010	Zoran Antonijevic José Paulo Pinheiro Parvin Fardipour Roger Lewis	2
+ PDF Chat	Adaptive Clinical Trials: The Promise and the Caution	2010	Donald A. Berry	2
+ PDF Chat	Spinal Cord Injury Neuroprotection and the Promise of Flexible Adaptive Clinical Trials	2013	William J. Meurer William G. Barsan	2
+ PDF Chat	Adaptive design methods in clinical trials – a review	2008	Shein‐Chung Chow Mark Chang	2
+ PDF Chat	Overview, hurdles, and future work in adaptive designs: perspectives from a National Institutes of Health-funded workshop	2012	Christopher S. Coffey Bruce Levin Christina Clark Cate Timmerman Janet Wittes Peter R. Gilbert Sara Harris	2
+	Scientific and Regulatory Reasons for Delay and Denial of FDA Approval of Initial Applications for New Drugs, 2000-2012	2014	Leonard Sacks Hala Shamsuddin Yuliya Yasinskaya Khaled Bouri Michael Lanthier Rachel E. Sherman	2
+	A Regulatory View on Adaptive/Flexible Clinical Trial Design	2006	Hung Hung Robert T. O’Neill Sue‐Jane Wang John Lawrence	2
+ PDF Chat	Are outcome-adaptive allocation trials ethical?	2015	Spencer Phillips Hey Jonathan Kimmelman	2
+	Adaptive clinical trials in oncology	2011	Donald A. Berry	2
+ PDF Chat	Commentary on Hey and Kimmelman	2015	J. Jack Lee	1
+	Group sequential methods in the design and analysis of clinical trials	1977	Stuart J. Pocock	1
+ PDF Chat	The hazards of randomized phase II trials	2011	Primo N. Lara Mary W. Redman	1
+	Learning versus confirming in clinical drug development*	1997	Lewis B. Sheiner	1
+ PDF Chat	Missing steps in a staircase: a qualitative study of the perspectives of key stakeholders on the use of adaptive designs in confirmatory trials	2015	Munyaradzi Dimairo Jonathan Boote Steven A. Julious J P Nicholl Susan Todd	1
+	Commentary on Hey and Kimmelman	2015	Donald A. Berry	1
+	Bayesian adaptive clinical trials: a dream for statisticians only?	2011	Sylvie Chevret	1
+	Adaptive Clinical Trials	2008	Christopher S. Coffey John A. Kairalla	1
+	Adaptive trial design: Its growing role in clinical research and implications for pharmacists	2011	Joshua Cirulli Wesley McMillian Mojdeh Saba David D. Stenehjem	1
+	How large should a phase II trial of a new drug be?	1987	Ronald Simon	1
+ PDF Chat	Adaptive Designs for Clinical Trials	2016	Deepak L. Bhatt Cyrus R. Mehta	1
+	Mixed Methods Research: A Guide to the Field	2016	Vicki L. Plano Clark Nataliya V. Ivankova	1
+ PDF Chat	Attitudes and opinions regarding confirmatory adaptive clinical trials: a mixed methods analysis from the Adaptive Designs Accelerating Promising Trials into Treatments (ADAPT-IT) project	2016	William J. Meurer Laurie J. Legocki Samkeliso Mawocha Shirley M. Frederiksen Timothy C. Guetterman William G. Barsan Roger Lewis Donald A. Berry Michael D. Fetters	1
+ PDF Chat	Opportunities and Challenges for Drug Development: Public–Private Partnerships, Adaptive Designs and Big Data	2016	Oktay Yıldırım Matthias Gottwald Peter Schüler Martin C. Michel	1
+	Infectious disease, human capital, and the BRICS economy in the time of COVID-19	2020	Devi Prasad Dash Narayan Sethi Aruna Kumar Dash	1
+	Statistics: A Bayesian Perspective	1997	Paul J. Smith Donald A. Berry	1
+	Bayesian Methods in Health-Related Research	2018		1
+	Adaptive Bayesian Designs for Dose-Ranging Drug Trials	2002	Donald A. Berry Peter Müller Andrew P. Grieve Michael K. Smith Tom Parke Richard Blazek Neil Mitchard Michael Krams	1
+	Bayesian Adaptive Methods for Clinical Trials	2010	Scott Berry Bradley P. Carlin J. Jack Lee Peter Müller	1
+	Innovative Approaches for Designing and Analyzing Adaptive Dose-Ranging Trials	2007	Björn Bornkamp Frank Bretz Alex Dmitrienko Greg Enas Brenda Gaydos Chyi‐Hung Hsu Franz König Michael Krams Qing Liu Beat Neuenschwander	1
+	Integrative Analysis Strategies for Mixed Data Sources	2011	Pat Bazeley	1
+	I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy	2009	AD Barker C C Sigman Kelloff Gj NM Hylton DA Berry L. Esserman	1
+ PDF Chat	Bayesian clinical trials at the University of Texas M. D. Anderson Cancer Center	2009	Swati Biswas Diane D. Liu J. Jack Lee Donald A. Berry	1
+	A Bayesian dose-finding trial with adaptive dose expansion to flexibly assess efficacy and safety of an investigational drug	2010	Scott Berry Walter Spinelli Gary S. Littman John Z. Liang Parvin Fardipour Donald A. Berry Roger Lewis Michael Krams	1
+	Adaptive designs for confirmatory clinical trials	2009	Frank Bretz Franz Koenig Werner Brannath Ekkehard Glimm Martin Posch	1
+	Statistics: A Bayesian Perspective	1995	Donald A. Berry	1
+	Adaptive Designs, Informed Consent, and the Ethics of Research	2001	Daryl Pullman Xikui Wang	1
+	The future of drug development: advancing clinical trial design	2009	John J. Orloff Frank L. Douglas José Cirı́aco Pinheiro Susan L. Levinson Michael Branson Pravin Chaturvedi Ene Ette Paul Gallo Gigi Hirsch Cyrus R. Mehta	1
+	Comments on the Draft Guidance on “Adaptive Design Clinical Trials for Drugs and Biologics” of the U.S. Food and Drug Administration	2010	Werner Brannath Hans Ulrich Burger Ekkehard Glimm Nigel Stallard Marc Vandemeulebroecke Gernot Wassmer	1
+ PDF Chat	Bayesian clinical trials in action	2012	J. Jack Lee Caleb T. Chu	1
+	Adaptive Clinical Trials	2012	William J. Meurer Roger Lewis Donald A. Berry	1